Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Inclusion Criteria:

• histologically confirmed solid malignancy
• scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2

Exclusion Criteria:

• pregnancy
• pelvic or abdominal radiation within 4 weeks
• uncontrolled brain metastasis
• other moderate or high emetic risk chemotherapy on day 2-5
• untreated gut obstruction
• known allergy or severe adverse effect from palonosetron or olanzapine
• AST/ ALT > 2.5x or serum creatinine clearance less than 50 ml/min